BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 17, Issue 2
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study
©The Author(s) 2026.
World J Diabetes. Feb 15, 2026; 17(2): 112867
Published online Feb 15, 2026. doi: 10.4239/wjd.v17.i2.112867
Table 6 Adverse events occurring in two groups of patients during the treatment process, n (%)
Parameter
CM group (n = 107)
CSCT group (n = 104)
χ²
P value
GI adverse events11 (10.28)15 (14.42)0.8380.360
Urinary tract infections5 (4.67)7 (6.73)0.4160.519
Hypoglycaemia10 (9.35)8 (7.69)0.1850.667
Nervous system disorders3 (2.80)5 (4.81)0.1610.688
Diabetic retinopathy2 (1.87)1 (0.96)0.0010.980
GI: Gastrointestinal; CM: Canagliflozin monotherapy; CSCT: Canagliflozin and semaglutide combination therapy.
Full Size Table
Write to the Help Desk
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.